KD3010

DB05188ExperimentalSmall molecule

KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.

Mechanism: KD3010 is a potent, orally administered, peroxisome proliferator-activated receptor-delta (PPARδ) agonist that exhibits ~1000-fold selectivity over PPARγ and PPARα. PPARδ regulates lipid catabolism and energy utilization in peripheral tissues. Activation of PPARδ reduces central adiposity, improves atherogenic lipid profiles, and increases glucose utilization/insulin sensitivity.
Curator reviewed
Primary indication: Investigated for use/treatment in metabolic disease and obesity.Curator reviewed
Formula / weight: C₃₀H₃₃F₃N₂O₈S₂ · 670.72 g/mol (avg)
Code names: KD-3010

Resolves to

Compound

UNIIDIO2QPE05JCAS934760-90-4

Structure

InChIKeySUTQDFLDQUPTKX-QVLMFNNZSA-NSMILESCC1=CC=C(C=C1)S(O)(=O)=O.[H]C1(CC2=C(C1)C(=CC=C2)S(=O)(=O)N1[C@@]([H])(C)CN(C[C@@]1([H])C)C1=CC=C(OC(F)(F)F)C=C1)C(O)=O

Targets

Q03181PPARD

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with KD3010, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account